









Markets
/
Stocks
/
nasdaq-agen
/

Agenus Inc

AGEN

2.940USD

+0.170+6.14%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

96.47MMarket Cap

LossP/E TTM



Agenus Inc

2.940

+0.170+6.14%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Agenus Inc

Currency: USD Updated: 2026-02-06

Key Insights

Agenus Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 126 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.33.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Agenus Inc's Score

Industry at a Glance

Industry Ranking

126 / 392

Overall Ranking

264 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Agenus Inc Highlights

StrengthsRisks

Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Undervalued

The company’s latest PE is -1.87, at a low 3-year percentile range.

Held by PRFDX

Star Investor PRFDX holds 24.50K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

12.333

Target Price

+345.25%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Agenus Inc is 7.39, ranking 115 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 30.23M, representing a year-over-year increase of 20.40%, while its net profit experienced a year-over-year increase of 196.12%.

Score

Industry at a Glance

Previous score

7.39

Change



Financials

3.40

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.40

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.49

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Agenus Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Agenus Inc is 8.46, ranking 42 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.87, which is -91.92% below the recent high of -0.15 and -97.98% above the recent low of -3.70.

Score

Industry at a Glance

Previous score

8.46

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 126/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Agenus Inc is 7.33, ranking 294 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 23.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

12.333

Target Price

+345.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Agenus Inc

AGEN

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Agenus Inc is 4.99, ranking 336 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.30 and the support level at 2.14, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.89

Change

0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.073

Sell

RSI(14)

40.332

Neutral

STOCH(KDJ)(9,3,3)

29.545

Buy

ATR(14)

0.203

Low Volatility

CCI(14)

-59.031

Neutral

Williams %R

72.619

Sell

TRIX(12,20)

-0.990

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

2.872

Buy

MA10

2.951

Sell

MA20

3.369

Sell

MA50

3.594

Sell

MA100

3.865

Sell

MA200

4.237

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Agenus Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 37.38%, representing a quarter-over-quarter decrease of 9.68%. The largest institutional shareholder is The Vanguard, holding a total of 2.83M shares, representing 7.83% of shares outstanding, with 18.39% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

2.57M

+1.46%

Invus Public Equities Advisors, LLC

1.06M

Morgan Stanley & Co. LLC

493.52K

-31.43%

BlackRock Institutional Trust Company, N.A.

468.79K

-4.27%

Armen (Garo H.)

367.59K

+2.58%

BofA Global Research (US)

369.31K

-12.21%

Millennium Management LLC

348.75K

-30.87%

Geode Capital Management, L.L.C.

346.99K

+9.32%

Walleye Capital LLC

310.79K

+56.74%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Agenus Inc is 3.96, ranking 113 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.61. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.